NANOGEN, INC.
Analyte specific reagents and related products to research and clinical reference laboratories for the development of tests for the detection of genetic mutations associated with diseases such as cystic fibrosis, Alzheimer’s, and cardiovascular disease
Founded in 1993 by H.C. Birndorf, Nanogen has developed technologies that integrated advanced microelectronics and molecular biology on proprietary semiconductor microchips. Among its top competitors are Affymetrix, Applera Corporation and Molecular Dynamics.
Howard C. Birndorf (CEO)
Nick Venuto (CFO)
David Ludvigson (COO)
Howard C. Birndorf (Chairman)
Frank H. Jellinek Jr.
David Schreiber
William G. Gerber
Stelios B. Papadopoulos
Robert E. Whalen
10398 Pacific Center Court
San Diego, CA 92121
USA
Phone: +1-877-626-6436
Fax: +1-858-410-4952
The Molecular Biology Workstation (MBW) is a multi-purpose research tool for the analysis and processing of the NanoChip™ cartridge.
Related patents
- Fluorescent cartridge for calibration of a microarray reader
- Integrated portable biological detection system
- Methods for the electronic, Homogeneous assembly and fabrication of devices
- Apparatus for active programmable matrix devices
- Protein biopolymer markers predictive of insulin resistance
- IG lambda biopolymer markers predictive of alzheimers disease
- Process for differential diagnosis of Alzheimer's dementia in patients exhibiting mild cognitive impairmen
- Protein biopolymer markers indicative of age matched control
- Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons
- Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
- Biopolymer marker indicative of disease state having a molecular weight of 1793 Daltons
Related news
- Nanogen Licenses Molecular Technology to Quest Diagnostics for In Vitro Diagnostic Testing
- Nanogen and HandyLab Conclude License and Supply Agreements for Real-Time PCR Diagnostics
- Nanogen Receives Award for 5-Year Growth Record Second Year in Deloitte's Technology Fast 50
- Nanogen Announces Combination with The Elitech Group
- Nanogen Reports 2008 Second Quarter Financial Results
- Nanogen to Host Second Quarter Conference Call August 14, 2008
- Nanogen Awarded New CDC Contract to Develop Molecular Diagnostic Test
- Nanogen Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
- Nanogen Announces Consolidation of Point of Care Manufacturing Operations
- Dutton Associates Announces Investment Opinion: Nanogen Strong Speculative Buy Rating In Update Coverage By Dutton Associates
- Nanogen and Thermo Fisher Scientific Partner to Provide Molecular-
- DRI Capital Inc. Acquires Royalties from Nanogen Inc. for US$10
- Nanogen to Host Fourth Quarter Conference Call March 13, 2008
- Nanogen Announces Retirement of CFO; Appoints Successor
- Nanogen Reaches Milestone in CDC Influenza Project
- Nanogen, Inc. Receives Notice Regarding Minimum Bid Price Rule
- Nanogen Strengthens Cardiac Biomarker Patent Position as US Patent Office Reissues Patent for Diagnosis of Chronic Congestive Heart Failure
- Nanogen to Close Array Business - Will Focus on Two High Growth Product Lines
- Nanogen to Close Array Business - Will Focus on Two High Growth
- Nanogen Extends IP Portfolio with Nucleic Acid Detection and Genotyping Technology Patents
- Nanogen to Focus on High Growth Clinical Diagnostics Markets with Real Time and Point of Care Products; Undertakes Evaluation of Strategic Alternatives for Microarray Business
- Nanogen Reports 2007 Second Quarter Financial Results
- Nanogen to Host Second Quarter Conference Call and Webcast on August
- Nanogen Gains Access to Schizophrenia Markers
- Nanogen Announces Collaboration with Canadian Agencies to Develop Veterinary and Bioterror Diagnostics
- Nanogen Reports 2007 First Quarter Financial Results
- Nanogen Submits 510(K) for Cystic Fibrosis Genetic Assay and NanoChip(R) 400 System
- Nanogen Obtains GSA Contract for NanoChip(R) 400 Platform
- Nanogen Awarded Patents for Biomarkers Associated with Diabetes, Alzheimers Disease
- Nanogen Reports 2006 Fourth Quarter and Year-End Financial Results
- Nanogen Releases Pharmacogenetics Research Reagents for CYP2C9 and VKORC1 Analysis
- Heiner Dreismann, Former Roche Executive, Joins Nanogen Board of Directors
- Nanogen Reports 2006 Third Quarter Financial Results 11/1/2006 4:00 PM
- Nanogen to Host Third Quarter Conference Call and Webcast on November 1, 2006
- Nanogen Awarded Additional Patents for Diabetes, Alzheimer's Disease Biomarkers
- Nanogen Announces Consolidation and Cost Reduction Actions
- Drug Royalty Corporation Inc. Acquires Royalties from Nanogen Inc. for $20 Million
- New Patent Expands Nanogen's Core Nanotechnology Position
- Nanogen Earns Patents for Use of Biomarkers Related to Diabetes and Alzheimers Disease
- Nanogen Expands Point-of-Care Product Line to Include Drugs of Abuse Tests
- Nanogen Reports 2006 Second Quarter Financial Results
- Fisher HealthCare to Distribute Nanogen Real-Time PCR Products to Clinical Laboratories
- Nanogen to Host Second Quarter Conference Call and Webcast on August 9
- Nanogen and Fisher Scientific Expand Molecular Diagnostics R&D Collaboration Agreement
- Nanogen Releases New Real-Time PCR Reagents
- Nanogen Releases Enterovirus Reagent Employing Newly Patented Hybridization Technology
- Nanogen Announces Type II Diabetes Research Collaboration
- Nanogen Reports 2006 First Quarter Financial Results
- Nanogen Receives $25 Million Equity Financing Commitment
- Nanogen to Release First Quarter Financial Results and Host Webcast on May 11, 2006 05/08/2006 08:00:00
- DrugMEt Pharmacogenetics Product Achieves CE Mark for IVD Use
- Nanogen to Acquire European Molecular Diagnostics Company Amplimedical
- Nanogen Earns Two Patents for Therapeutic and Diagnostic Use of Biomarkers
- Nanogen Receives 510(k) Clearance for StatusFirst(TM) Congestive Heart Failure NT-proBNP Test
- Nanogen Launches Cystic Fibrosis Analyte Specific Reagents
- Nanogen and Fisher Scientific to Expand Reach Into Molecular Diagnostics
- Nanogen Issued Patent for Integrated Sample Preparation and Detection Device
- Nanogen Issued Patent for Integrated Sample Preparation and Detection Device
- Nanogen Reports Preliminary 2005 Fourth Quarter and Year-End Financial Results
- Nanogen Closes Acquisition of Point-of-Care Cardiac Diagnostic Test Business From Spectral Diagnostics